PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 25, 2026Diabetes Obesity and Metabolism4 citationsOpen Access

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

View Full Paper
RORune Viig OvergaardOBOscar BirkhanNRNaveen Rathor

Key Points

  • This research aims to evaluate the efficacy and safety of oral semaglutide 25 mg for treating obesity in individuals with and without type 2 diabetes.
  • Compared estimated exposure levels and efficacy of oral semaglutide 25 mg with subcutaneous semaglutide 2.4 mg.
  • Utilized a model-informed drug development approach.
  • Efficacy levels of oral semaglutide 25 mg were similar to those of subcutaneous semaglutide 2.4 mg.
  • Support for using oral semaglutide 25 mg in treating obesity with/without type 2 diabetes.

Abstract

Estimated exposure levels and efficacy observed with oral semaglutide 25 mg were similar to those obtained with subcutaneous semaglutide 2.4 mg, supporting application of oral semaglutide 25 mg to treat individuals with overweight/obesity, with/without T2D.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Overgaard et al. (2026) studied this question.

synapsesocial.com/papers/69ec5b2388ba6daa22daca5fhttps://doi.org/10.1111/dom.70769
Ask AI
Helpful
Bookmark
Share
View Full Paper